Cue Biopharma Inc. (CUE)
0.76
-0.02 (-2.44%)
At close: Apr 17, 2025, 3:59 PM
0.79
3.79%
Pre-market: Apr 21, 2025, 08:22 AM EDT
-2.44% (1D)
| Bid | 0.72 |
| Market Cap | 57.42M |
| Revenue (ttm) | 9.29M |
| Net Income (ttm) | -40.67M |
| EPS (ttm) | -0.72 |
| PE Ratio (ttm) | -1.06 |
| Forward PE | -1.86 |
| Analyst | Buy |
| Ask | 0.82 |
| Volume | 111,540 |
| Avg. Volume (20D) | 207,311 |
| Open | 0.77 |
| Previous Close | 0.78 |
| Day's Range | 0.76 - 0.80 |
| 52-Week Range | 0.45 - 2.26 |
| Beta | 2.03 |
About CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-10...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2018
Employees 41
Stock Exchange NASDAQ
Ticker Symbol CUE
Website https://www.cuebiopharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CUE stock is "Buy." The 12-month stock price forecast is $2.5, which is an increase of 228.08% from the latest price.
Stock ForecastsNext Earnings Release
Cue Biopharma Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+5.35%
Cue Biopharma shares are trading higher. Citizens ...
Unlock content with
Pro Subscription
2 weeks ago
-17.67%
Cue Biopharma shares are trading lower. The company reported FY24 financial results.
